States Question Costs Of Middlemen That Manage Medicaid Drug Benefits
Published by NPR
Several states are questioning the cost of using pharmacy middlemen to manage their prescription drug programs in a movement that could shake up the complex system that manages how pharmaceuticals are priced and paid for.
The debate is playing out this week in an Ohio courtroom, as the state fights to release a report detailing what it paid two middlemen, CVS Health and Optum, to manage its Medicaid program’s prescription drug plans.
The report shows that the companies charged the state 8.8 percent more than they paid to pharmacies to fill prescriptions. The companies kept the more than $224 million difference between what they charged the state and paid for the drugs.
“I would love to tell you that 8.8 percent is too high, too low, or normal, but I’m really unqualified to say that because our state Medicaid program is the first state in the country to really get this level of transparency into how this works,” says Antonio Ciaccia, the director of government affairs for the Ohio Pharmacists Association.
But he added, “I think 8.8 percent is insane.”
Ohio’s Medicaid program is run almost completely through private managed care insurance companies. Those companies in turn contract with CVS Health and Optum to manage the prescription drug portion of recipients’ coverage. The companies — known as pharmacy benefit managers, or PBMs — negotiate discounts from drugmakers and work hard to keep the prices they actually pay secret.
Recent Posts
-
Senior Care Pharmacy Coalition Opposes CMS Final Rule on Minimum Staffing Standards for LTC Facilities
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy sector, released a statement today regarding its opposition to the Centers for Medicare & Medicaid Services (CMS) final rule on minimum staffing standards for long-term care (LTC) facilities.
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.